CCND1
CCND1 encodes Cyclin D1, a master regulator of the cell cycle that governs the transition from the G1 to the S phase. Over-expression of CCND1 is a primary driver of uncontrolled cell growth in diverse cancers, including breast cancer and Mantle Cell Lymphoma.
Key Takeaways
- •CCND1 is the "accelerator" that tells a cell it is time to divide.
- •It works by activating CDK4/6, which then disables the Retinoblastoma (RB) "brake."
- •The G870A variant (rs9344) influences how the protein is made and is linked to cancer risk.
- •Modern cancer drugs (CDK4/6 inhibitors) work by blocking the machinery that CCND1 activates.
Basic Information
- Gene Symbol
- CCND1
- Full Name
- Cyclin D1
- Also Known As
- BCL1D11S287EPRAD1U21B31
- Location
- 11q13.3
- Protein Type
- Cell Cycle Regulator
- Protein Family
- Cyclin family
Related Isoforms
The canonical full-length protein responsible for the majority of cell cycle control.
An alternatively spliced variant that lacks the C-terminal nuclear export signal, leading to its constitutive nuclear localization and increased oncogenic potential.
Key SNPs
The most studied functional variant; the A allele favors the production of the more oncogenic Cyclin D1b isoform and is associated with earlier onset of various cancers.
Common marker used in GWAS panels to identify the CCND1 locus and its association with colorectal cancer risk and metabolic traits.
Studied for its potential regulatory effects on CCND1 expression levels in diverse tissue contexts.
Overview
CCND1 (Cyclin D1) is a critical member of the cyclin family, a group of proteins that regulate the timing and precision of the cell cycle. Cyclin D1 acts as the sensor for growth factors in the environment. When a cell detects that it is time to grow, CCND1 levels rise, allowing the cell to cross the "Restriction Point"—the point of no return after which the cell is committed to dividing.
In healthy tissue, CCND1 is tightly controlled and produced only when needed for repair or growth. However, CCND1 is one of the most frequently over-expressed oncogenes in human cancer. Whether through genetic amplification or chromosomal translocations, excess Cyclin D1 forces the cell cycle into a state of perpetual "on," leading to the rapid and uncontrolled proliferation that characterizes tumors of the breast, lung, and blood.
Conceptual Model
A simplified mental model for the pathway:
CCND1 turns environmental "permission" into the physical "action" of cell division.
Core Health Impacts
- • Cell Cycle Entry: Master regulator of the G1 to S phase transition in dividing cells
- • Cellular Proliferation: Directly dictates the rate of tissue growth and regeneration after injury
- • Oncogenesis: Pathological over-expression drives the development of Mantle Cell Lymphoma and Breast Cancer
- • Metabolic Balance: Influences glucose homeostasis and adipocyte differentiation through non-cell cycle pathways
- • Tissue Repair: Essential for the rapid expansion of progenitor cells during skin and gut healing
Protein Domains
Cyclin Box
A conserved structural motif required for the physical binding and activation of CDK4 and CDK6.
CDK Interaction Face
Specific residues that facilitate the formation of the active kinase complex.
PEST Sequence
A C-terminal region that signals the protein for rapid degradation, ensuring the "accelerator" is only active briefly.
Upstream Regulators
Growth Factors (Wnt, Notch) Activator
Primary extracellular signals that induce the rapid transcription of the CCND1 gene.
CDK4 / CDK6 Activator
The obligate catalytic partners; CCND1 must bind to these kinases to perform its signaling duties.
NF-κB Activator
Inflammatory signal that upregulates CCND1, linking chronic inflammation to cancer risk.
Estrogen Activator
Potent driver of CCND1 in breast tissue; explains the hormone-dependent nature of many breast cancers.
MYC Activator
Master oncogenic transcription factor that directly activates the CCND1 promoter.
Downstream Targets
Retinoblastoma Protein (RB1) Activates
The primary target; CCND1-CDK4/6 complexes phosphorylate RB to release the brake on the cell cycle.
E2F Transcription Factors Activates
Released from RB inhibition, these factors turn on the genes required for DNA synthesis.
Cell Cycle Entry (G1/S) Activates
The global biological outcome; the definitive commitment of the cell to replicate its DNA.
p21 / p27 Inhibits
Cell cycle inhibitors that CCND1-CDK4/6 complexes sequester to prevent them from stopping the cycle.
Cellular Proliferation Activates
The final physiological result; an increase in the total number of cells in a tissue or tumor.
Role in Aging
CCND1 is a central mediator of "proliferative aging." As we age, the regulation of Cyclin D1 becomes less precise, contributing to both the age-related decline in tissue regenerative capacity and the exponential increase in cancer risk seen in the elderly.
Regenerative Burnout
Chronic activation of the CCND1 pathway in stem cells can lead to premature exhaustion of the body's repair reserves.
Senescence Trigger
Inappropriately high CCND1 signaling can trip the cell's "oncogene-induced senescence" alarm, creating zombie-like cells.
Metabolic Decay
Age-related declines in the precision of CCND1 control in the liver and pancreas impact systemic glucose management.
Cancer Latency
Cumulative mutations that deregulate CCND1 are a primary reason why cancer risk peaks in late life.
Inflammaging Link
Chronic low-grade inflammation (NF-κB) persistently drives CCND1, creating a pro-growth background for aging tissues.
Sarcopenia Link
Impaired CCND1-mediated expansion of muscle satellite cells contributes to the loss of muscle mass in the elderly.
Disorders & Diseases
Mantle Cell Lymphoma (MCL)
Driven by the t(11;14) translocation, which places CCND1 next to the IgH promoter, causing permanent over-expression.
Breast Cancer (ER+)
CCND1 is amplified in up to 15% of breast cancers and over-expressed in 50%, driving estrogen-fueled growth.
Multiple Myeloma
Subsets of myeloma are characterized by CCND1 translocations, identifying a specific patient group for targeted therapy.
Head and Neck Squamous Cell Carcinoma
Frequent amplification of the CCND1 locus on chromosome 11 is a marker of aggressive disease and poor prognosis.
Colorectal Cancer
Wnt-driven over-expression of CCND1 is an early and essential event in the development of colon polyps and tumors.
The Restriction Point Failure
In healthy cells, the "Restriction Point" is a high-security gate. If the cell is damaged, it stays closed. In CCND1-driven cancers, this gate is effectively smashed open, allowing damaged cells to replicate their DNA regardless of safety signals.
Interventions
Supplements
Polyphenol studied for its ability to downregulate CCND1 expression by inhibiting the NF-κB and Wnt pathways.
Reported to induce cell cycle arrest in tumor cells by decreasing the stability of the Cyclin D1 protein.
VDR signaling can antagonize the CCND1 promoter, acting as a natural brake on hyper-proliferation in some tissues.
Reported to interfere with the signaling cascades that drive CCND1 transcription in cancer prevention models.
Lifestyle
Helps manage the systemic insulin and growth factor levels that keep CCND1 signaling within a healthy physiological range.
Reduces the chronic insulin/IGF-1 spikes that can over-stimulate the CCND1-CDK4/6 growth machinery.
The cell cycle follows a circadian rhythm; sleep deprivation can disrupt the orderly turnover of Cyclin D1.
Lowering chronic cortisol prevents the hormonal dysregulation that can impact cell cycle timing in various organs.
Medicines
A targeted CDK4/6 inhibitor that blocks the kinase machinery activated by CCND1; used primarily in ER+ breast cancer.
Other members of the CDK4/6 inhibitor class that effectively "re-engage the brake" on CCND1-driven cell growth.
Works in the breast to block estrogen receptors, thereby cutting off the hormonal signal that induces CCND1.
Blocks the PI3K/Akt/mTOR pathway that upregulates CCND1 translation in response to nutrient signals.
Lab Tests & Biomarkers
Protein Expression
Standard pathology test used to confirm the diagnosis of Mantle Cell Lymphoma in tissue biopsies.
Molecular test to detect extra copies of the CCND1 gene, used to guide prognosis in breast and head/neck cancers.
Cell Cycle Markers
Measures the percentage of cells actively dividing, a clinical reflection of the total CCND1 "output" in a tumor.
Research marker indicating that the CCND1-CDK4/6 pathway has successfully disabled the cell cycle brake.
Genetic Screening
Assesses the G870A variant to understand the baseline genetic predisposition toward the more aggressive Cyclin D1b isoform.
Hormonal Interactions
Estrogen Primary Activator
Directly induces CCND1 transcription in the breast and uterus, driving normal and malignant proliferation.
Insulin / IGF-1 Activator
Metabolic hormones that signal nutrient availability to turn on the CCND1 growth accelerator.
Cortisol Modulator
Exerts complex, tissue-specific effects on the cell cycle, often acting as a brake in healthy tissues but a promoter in some cancers.
Androgens Activator
Can drive CCND1 expression in prostate tissue, contributing to both normal growth and cancer progression.
Deep Dive
Network Diagrams
CCND1: The Cell Cycle Accelerator
The Master Accelerator: CCND1 and the G1/S Transition
To understand CCND1, one must view the cell cycle as a high-security vault. The “treasure” inside is the cell’s DNA, and the vault only opens during the S-phase when the DNA is copied. CCND1 is the master key that unlocks the first gate.
The Sensor: Cyclin D1 is short-lived and very sensitive. It is the cell’s “growth factor sensor.” When the cell receives a signal to grow (from estrogen, insulin, or an injury), it builds a small amount of CCND1.
Activating the Engine: CCND1 cannot work alone. It must find and bind to its partners, CDK4 or CDK6. Together, they form an active enzymatic engine. This engine then performs the most important task in biology: it disables the Retinoblastoma (RB) protein. RB is the biological “brake” that holds back the cell cycle. Once CCND1 removes the brake, the vault opens, and the cell is irrevocably committed to dividing.
The Oncogene of Proliferation: CCND1 and Cancer
Because CCND1 is the “accelerator” for cell division, it is one of the most dangerous genes if it becomes dysregulated.
Mantle Cell Lymphoma: The most famous example of CCND1 gone wrong is Mantle Cell Lymphoma. In this cancer, a chromosomal mistake (translocation) places the CCND1 gene right next to an “always on” switch. The result is a cell that is constantly producing the growth accelerator, forcing the white blood cells to divide uncontrollably.
Breast Cancer: In over half of all breast cancers, the CCND1 pathway is hyper-active. Often, the cell simply builds too many copies of the gene (amplification). This creates a surplus of Cyclin D1 that overwhelms the cell’s natural brakes, allowing the tumor to grow even when it should be resting. This is why testing for CCND1 activity is a requirement for choosing the best treatment for breast cancer patients today.
The Cyclin D1b Variant: A Hidden Danger
The study of CCND1 genetics identified a “stealth” version of the protein called Cyclin D1b.
The rs9344 Switch: A common genetic variant (rs9344) determines how the CCND1 instructions are read. Individuals with the “A” version of this variant are more likely to produce the D1b isoform.
Escape from Control: Normally, the cell has a “disposal tag” on the CCND1 protein that tells the cell to destroy it once the gate is open. The D1b version is missing this tag. It stays in the cell nucleus longer than it should, providing a continuous growth signal. Carriers of this variant often have an earlier onset of cancer and a more aggressive disease course, proving that the precision of timing is just as important as the signal itself in the human cell cycle.
Practical Note: The Threshold of Growth
Accelerator vs. Brake. Most people focus on "cancer genes" as being broken. CCND1 is a "power" gene that is usually *too good* at its job. It is like a car with a stuck accelerator pedal. The goal of modern treatment is not to replace the gene, but to use "emergency brakes" like CDK4/6 inhibitors to stop the runaway growth.
Genetics and Risk. If you have a family history of breast cancer or lymphoma, your CCND1 genotype (like the G870A variant) is a "risk modifier." It doesn't cause cancer on its own, but it determines how easily your cells can be "pushed" into dividing by hormones or inflammation.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The definitive early review establishing CCND1 as the primary integrator of environmental signals and cell cycle entry.
Pivotal clinical study identifying the high frequency of CCND1 deregulation in human breast cancer cohorts.
Discovered the Cyclin D1b isoform and established its superior ability to drive uncontrolled growth compared to the normal protein.
The PALOMA-2 trial results proving that blocking the machinery CCND1 activates is a highly effective cancer treatment.
Revealed that CCND1 has vital functions beyond the cell cycle, including the regulation of glucose and fat metabolism.